Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus

被引：0
|
作者：
Jung-Im Shin
机构：
[1] Johns Hopkins University,Department of Epidemiology
[2] and Clinical Research,The Welch Center for Prevention, Epidemiology
来源：
Current Diabetes Reports | 2019年 / 19卷
关键词：
Second-line glucose-lowering therapy; Type 2 diabetes mellitus; Clinical guidelines; Cardiovascular outcome trials;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus
    Shin, Jung-Im
    CURRENT DIABETES REPORTS, 2019, 19 (08)
  • [2] Are patients with schizophrenia treated less with second-line glucose-lowering drugs for type 2 diabetes?
    Jacobsen, Soren L.
    Kohler-Forsberg, Ole
    Rohde, Christopher
    SCHIZOPHRENIA RESEARCH, 2024, 270 : 231 - 234
  • [3] Quality of life in patients with type 2 diabetes initiating a second-line glucose-lowering therapy: the global DISCOVER study
    Nicolucci, A.
    Gomes, M. B.
    Khunti, K.
    Kosiborod, M.
    Pocock, S.
    Rathmann, W.
    Shestakova, M. V.
    Shimomura, I.
    Watada, H.
    Chen, H.
    Cid-Ruzafa, J.
    Fenici, P.
    Hammar, N.
    Tang, F.
    Ji, L.
    DIABETOLOGIA, 2018, 61 : S173 - S174
  • [4] Durability of Second-Line Oral Glucose-Lowering Therapy in Type 2 Diabetes: Results of a Large UK Cohort Study
    Mamza, Jil
    Mehta, Raj
    Donnelly, Richard
    Idris, Iskandar
    DIABETES, 2015, 64 : A39 - A39
  • [5] Newer second-line glucose-lowering drugs versus thiazolidinediones and cirrhosis risk in type 2 diabetes
    Yang, Jeff Y.
    Alexopoulos, Anastasia
    Moon, Andrew M.
    Kim, Hannah
    Pate, Virginia
    Barritt, A. Sidney
    Sturmer, Til
    Buse, John B.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 606 - 606
  • [6] Are patients with schizophrenia treated less with second-line glucose-lowering drugs for type 2 diabetes? Response
    Bennett, Melanie E.
    Calkins, Monica E.
    Dickerson, Faith
    Kreyenbuhl, Julie
    Medoff, Deborah
    SCHIZOPHRENIA RESEARCH, 2024, 270 : 235 - 236
  • [7] Health-related quality of life in patients with type 2 diabetes initiating a second-line glucose-lowering therapy: The DISCOVER study
    Nicolucci, Antonio
    Chen, Hungta
    Cid-Ruzafa, Javier
    Cooper, Andrew
    Fenici, Peter
    Gomes, Marilia B.
    Hammar, Niklas
    Khunti, Kamlesh
    Kosiborod, Mikhail
    Leigh, Paul
    Medin, Jennie
    Rathmann, Wolfgang
    Shestakova, Marina, V
    Shimomura, Iichiro
    Siddiqui, Afrah
    Tang, Fengming
    Watada, Hirotaka
    Ji, Linong
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2021, 180
  • [8] Comparison of Glucose-Lowering Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis
    Gu, Shuyan
    Hu, Xiaoqian
    Zhen, Xuemei
    Shi, Lizheng
    Shao, Hui
    Sun, Xueshan
    Gu, Yuxuan
    Huang, Minzhuo
    Dong, Hengjin
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (18)
  • [9] Is It Enough Glucose-Lowering Therapy for Men with Type 2 Diabetes Mellitus and Testosterone Deficiency?
    Khripun, Irina A.
    Bova, Elena V.
    Vorobyev, Sergey V.
    Dzantieva, Elizaveta O.
    Belousov, Igor I.
    Kogan, Michail I.
    DIABETES, 2017, 66 : A399 - A399
  • [10] Initiation of glucose-lowering therapy in Type 2 diabetes mellitus patients in general practice
    Spoelstra, JA
    Stolk, RP
    Klungel, OH
    Erkens, JA
    Rutten, GEHM
    Leufkens, HGM
    Grobbee, DE
    DIABETIC MEDICINE, 2004, 21 (08) : 896 - 900
12345